September 16, 2021

How to Invest in Early Stage Private Psychedelic Companies | Origin Therapeutics (ORIG)

Midas Letter
Midas Letter
How to Invest in Early Stage Private Psychedelic Companies | Origin Therapeutics (ORIG)

Have you ever wished you could invest in an early-stage psychedelic company before it went public? What about gaining exposure to a diverse portfolio of many private shroom boom companies? Early-stage investing has risks, but the rewards can be life-changing. Well, an actively managed investment issuer is doing the hard work for you and is set to go public in Q4 of 2021. Origin Therapeutics Holdings Inc (Proposed for listing on CNSX:ORIG)

“Normally, only venture capitalist, high net worth investors, angel investors might only, traditionally, have access to these privately held companies in the proof of concept stage. We are providing retail investors access to that, to capture that upside” – Origin Therapeutics CEO Alexander Somjen

A stock of stocks, per se. The company’s investment strategy is a time-tested due diligence process implemented to filter out only the most lucrative opportunities for investors. And with the psychedelics industry slated to become a $100 billion market opportunity, investing in the right stocks/drugs could prove to be advantageous.

As well as investing in their private companies, Origin Therapeutics also supports the companies they invest in with advisory or board positions.

The company’s founding shareholders and board members know a thing or two about capital markets and drug industries. Origin Therapeutics operational team has been early investors of companies you may have heard of, such as Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF, TSE:CWEB), MedReleaf Corp and ICC Labs Inc both purchased by Aurora Cannabis Inc (TSE:ACB, NASDAQ:ACB), Cybin Inc (NYSEAMERICAN:CYBN), and Green Thumb Industries Inc (OTCMKTS:GTBIF, CNSX:GTII).

Watch the full interview to learn how to gain exposure to psychedelic companies you wouldn’t generally have access to and for a great introduction to the Origin Therapeutics business.


00:00 – Origin Therapeutics CEO Alexander Somjen

00:53 – Origin Therapeutics business overview

01:46 – Early stage access to private companies

02:22 – Capital raise

02:50 – Investing model

03:12 – Shares outstanding

03:28 – Operational team members

04:45 – Operational team historical market value creation

05:35 – Psychedelic total addressable market (TAM)

06:31 – Cannabis vs psychedelic industries

08:20 – Psychedelic medicine timeline

09:05 – Controlling psychedelic dosages

10:28 – Timeline until public listing

Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.